B.C. Cho

403 total citations
33 papers, 280 citations indexed

About

B.C. Cho is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Molecular Biology. According to data from OpenAlex, B.C. Cho has authored 33 papers receiving a total of 280 indexed citations (citations by other indexed papers that have themselves been cited), including 28 papers in Pulmonary and Respiratory Medicine, 27 papers in Oncology and 5 papers in Molecular Biology. Recurrent topics in B.C. Cho's work include Lung Cancer Treatments and Mutations (27 papers), Colorectal Cancer Treatments and Studies (12 papers) and Cancer Immunotherapy and Biomarkers (8 papers). B.C. Cho is often cited by papers focused on Lung Cancer Treatments and Mutations (27 papers), Colorectal Cancer Treatments and Studies (12 papers) and Cancer Immunotherapy and Biomarkers (8 papers). B.C. Cho collaborates with scholars based in South Korea, United States and United Kingdom. B.C. Cho's co-authors include Christina S. Baik, Wu‐Chou Su, Helena A. Yu, Enriqueta Felip, Viola W. Zhu, Roland E. Knoblauch, Myung‐Ju Ahn, Robert C. Doebele, Shanna Stopatschinskaja and W. Marston Linehan and has published in prestigious journals such as International Journal of Radiation Oncology*Biology*Physics, Annals of Oncology and Journal of Thoracic Oncology.

In The Last Decade

B.C. Cho

30 papers receiving 277 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
B.C. Cho South Korea	8	232	204	90	47	27	33	280
Christina J. Falcon United States	11	215 0.9×	183 0.9×	98 1.1×	64 1.4×	17 0.6×	22	304
Stephanie P.L. Saw Singapore	6	166 0.7×	138 0.7×	68 0.8×	54 1.1×	26 1.0×	14	278
J.-S. Lee South Korea	7	200 0.9×	268 1.3×	66 0.7×	37 0.8×	14 0.5×	17	310
Giulia Grizzi Italy	12	185 0.8×	262 1.3×	82 0.9×	70 1.5×	41 1.5×	24	370
M.R. García Campelo Spain	9	301 1.3×	284 1.4×	119 1.3×	90 1.9×	19 0.7×	35	387
J.C.-H. Yang Taiwan	5	281 1.2×	263 1.3×	94 1.0×	46 1.0×	18 0.7×	12	353
Kaoru Irisa Japan	9	236 1.0×	214 1.0×	76 0.8×	48 1.0×	24 0.9×	16	333
E‐E Ke China	8	239 1.0×	200 1.0×	80 0.9×	51 1.1×	32 1.2×	12	315
Ulpiano Jiménez Spain	6	281 1.2×	236 1.2×	86 1.0×	61 1.3×	30 1.1×	12	334
Kartik Konduri United States	8	168 0.7×	260 1.3×	107 1.2×	34 0.7×	21 0.8×	27	365

Countries citing papers authored by B.C. Cho

Since Specialization

Citations

This map shows the geographic impact of B.C. Cho's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by B.C. Cho with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites B.C. Cho more than expected).

Fields of papers citing papers by B.C. Cho

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by B.C. Cho. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by B.C. Cho. The network helps show where B.C. Cho may publish in the future.

Co-authorship network of co-authors of B.C. Cho

This figure shows the co-authorship network connecting the top 25 collaborators of B.C. Cho. A scholar is included among the top collaborators of B.C. Cho based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with B.C. Cho. B.C. Cho is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Chau, Ian, B.C. Cho, M-H. Chen, et al.. (2025). 2094O SKYSCRAPER-07: A phase III, randomised study of atezolizumab (atezo) with or without tiragolumab (tira) in patients (pts) with unresectable esophageal squamous cell carcinoma (ESCC) that has not progressed following definitive concurrent chemoradiotherapy (dCRT). Annals of Oncology. 36. S1101–S1102.

Liu, Stephen V., Patrick M. Forde, Jarushka Naidoo, et al.. (2024). 90P Real-world (RW) post-progression outcomes and treatment (tx) patterns after first-line (1L) immuno-oncology (IO) regimens in patients (pts) with metastatic (m) NSCLC: CORRELATE. ESMO Open. 9. 102669–102669.

Park, Sojung, Hee Kyung Ahn, Young Joo Min, et al.. (2023). MA13.11 Lazertinib for Patients with NSCLC Harboring Uncommon EGFR Mutations: A Single-Arm, Phase II Multi-Center Trial. Journal of Thoracic Oncology. 18(11). S148–S149. 2 indexed citations

Paz‐Ares, Luis, M-J. Ahn, Aaron Lisberg, et al.. (2023). 1314MO TROPION-Lung05: Datopotamab deruxtecan (Dato-DXd) in previously treated non-small cell lung cancer (NSCLC) with actionable genomic alterations (AGAs). Annals of Oncology. 34. S755–S756. 30 indexed citations

Cho, B.C., Enriqueta Felip, Alexander I. Spira, et al.. (2023). LBA14 Amivantamab plus lazertinib vs osimertinib as first-line treatment in patients with EGFR-mutated, advanced non-small cell lung cancer (NSCLC): Primary results from MARIPOSA, a phase III, global, randomized, controlled trial. Annals of Oncology. 34. S1306–S1306. 47 indexed citations

Langen, J. De, B.C. Cho, Zofia Piotrowska, et al.. (2022). 1188TiP ORCHARD platform study: Osimertinib + datopotamab deruxtecan (Dato-DXd) cohort in patients (pts) with advanced NSCLC (aNSCLC) who have progressed on first-line (1L) osimertinib. Annals of Oncology. 33. S1091–S1092. 6 indexed citations

Ahn, M-J., et al.. (2022). LBA12 Tumour genomics in patients (pts) with epidermal growth factor receptor-mutated (EGFRm) advanced NSCLC treated with first-line (1L) osimertinib in the phase II ELIOS study. Annals of Oncology. 33. S1563–S1564. 4 indexed citations

Cho, B.C., Delvys Rodríguez‐Abreu, Maen Hussein, et al.. (2021). LBA2 Updated analysis and patient-reported outcomes (PROs) from CITYSCAPE: A randomised, double-blind, phase II study of the anti-TIGIT antibody tiragolumab + atezolizumab (TA) versus placebo + atezolizumab (PA) as first-line treatment for PD-L1+ NSCLC. Annals of Oncology. 32. S1428–S1428. 19 indexed citations

Yu, Helena A., Helen Ambrose, Christina S. Baik, et al.. (2021). 1239P ORCHARD osimertinib + savolitinib interim analysis: A biomarker-directed phase II platform study in patients (pts) with advanced non-small cell lung cancer (NSCLC) whose disease has progressed on first-line (1L) osimertinib. Annals of Oncology. 32. S978–S979. 31 indexed citations

10.

Han, Yeongcheol, Sangbin Lim, Hye Ryun Kim, et al.. (2021). P50.09 Characteristics and Clinical Outcomes of HER2 Mutated Non-small Cell Lung Cancer Patients Detected by NGS in Routine Clinical Practice. Journal of Thoracic Oncology. 16(10). S1117–S1118. 1 indexed citations

11.

Soo, Ross A., Georgia Dimopoulou, B.C. Cho, et al.. (2021). VP3-2021: A randomized phase II study of second-line osimertinib (Osi) and bevacizumab (Bev) versus Osi in advanced non-small-cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) and T790M mutations (mt): Results from the ETOP BOOSTER trial. Annals of Oncology. 32(7). 942–944. 7 indexed citations

12.

Hong, Min Hee, Do‐Kyun Kim, Sangbin Lim, et al.. (2021). 860MO Preoperative durvalumab (D) with or without tremelimumab (T) for resectable head and neck squamous cell carcinoma (HNSCC). Annals of Oncology. 32. S787–S787. 6 indexed citations

13.

Park, K., Enriqueta Felip, Rémi Veillon, et al.. (2019). Tepotinib in NSCLC patients harboring METex14 skipping: Cohort A of phase II VISION study. Annals of Oncology. 30. ix22–ix23. 6 indexed citations

14.

Yun, Jun-Won, Seokhyeon Jeong, Min Hee Hong, et al.. (2019). P1.01-94 JNJ-61186372, an EGFR-cMet Bispecific Antibody, in EGFR Exon 20 Insertion-Driven Advanced NSCLC. Journal of Thoracic Oncology. 14(10). S397–S398. 1 indexed citations

15.

Park, K., Myung‐Ju Ahn, Min Hee Hong, et al.. (2018). OA10.06 A First-in-Human Phase 1 Trial of the EGFR-cMET Bispecific Antibody JNJ-61186372 in Patients with Advanced Non-Small Cell Lung Cancer (NSCLC). Journal of Thoracic Oncology. 13(10). S344–S345. 7 indexed citations

16.

Linehan, W. Marston, D. Kim, Alexander Drilon, et al.. (2018). OA02.02 Safety and Preliminary Clinical Activity of Ropotrectinib (TPX-0005), a ROS1/TRK/ALK Inhibitor, in Advanced ROS1 Fusion-Positive NSCLC. Journal of Thoracic Oncology. 13(10). S322–S322. 5 indexed citations

17.

Kato, Ken, Manish A. Shah, Peter C. Enzinger, et al.. (2018). Phase III KEYNOTE-590 study of chemotherapy + pembrolizumab versus chemotherapy + placebo as first-line therapy for patients (Pts) with advanced esophageal or esophagogastric junction (E/EGJ) cancer. Annals of Oncology. 29. viii268–viii269. 7 indexed citations

18.

Kim, Jong Hoon, et al.. (2017). P3.01-028 Efficacy of Osimertinib for Brain Metastasis in Advanced NSCLC: Data from Single Center in ASTRIS Trial. Journal of Thoracic Oncology. 12(11). S2211–S2211. 1 indexed citations

19.

Hong, Min Hee, et al.. (2017). MA 12.01 A Phase Ib Study of the Combination of Afatinib and Ruxolitinib in EGFR Mutant NSCLC Progressed on EGFR-TKI: An Updated Analysis. Journal of Thoracic Oncology. 12(11). S1847–S1847. 1 indexed citations

20.

Lim, Sung Mook, B.C. Cho, Jin Sun Lee, et al.. (2016). Ceritinib in ROS1-rearranged non-small-cell lung cancer: a Korean nationwide phase II study. Annals of Oncology. 27. vi417–vi417. 7 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact